Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Cell Mol Neurobiol ; 19(1): 177-89, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10079976

ABSTRACT

1. Based upon the intriguing report that nitric oxide synthase (NOS) inhibitor dose-dependently reverses N-methyl-D-aspartate (NMDA)-induced neurotoxicity observed in primary cortical cell cultures, many laboratories have investigated whether NOS inhibition is beneficial as a treatment for cerebral ischemia. 2. Although the results are variable, it is likely thought that nitric oxide plays a key role in pathomechanism underlying ischemic brain damage. 3. We review the experimental studies on effects of NOS inhibition on cerebral ischemia and measuring nitric oxide produced in the brain subjected to cerebral ischemia. 4. Finally, the possibility of NOS inhibitors as a therapeutical tool is discussed.


Subject(s)
Brain Damage, Chronic/etiology , Brain Damage, Chronic/metabolism , Brain Ischemia/etiology , Brain Ischemia/metabolism , Nitric Oxide/physiology , Animals , Brain Damage, Chronic/enzymology , Brain Ischemia/enzymology , Nitric Oxide Synthase/metabolism
2.
Sex Transm Dis ; 25(9): 489-93, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9800262

ABSTRACT

BACKGROUND AND OBJECTIVES: Recently, a reduction in the susceptibility of clinical isolates of Neisseria gonorrhoeae to newer fluoroquinolones including sparfloxacin in vitro has been recognized in Japan. The quinolone resistance mechanisms in gonococcal isolates from a patient with clinical failure of sparfloxacin treatment was investigated. GOAL: To report a man with gonococcal urethritis in whom clinical failure of sparfloxacin treatment occurred and to examine the quinolone resistance mechanisms in gonococcal isolates from the patient. STUDY DESIGN: A man with gonococcal urethritis was treated with oral 100 mg sparfloxacin three times daily for 5 days. However, clinical failure of the sparfloxacin treatment was observed. The antimicrobial susceptibilities of pretreatment and posttreatment isolates to sparfloxacin and other agents were measured. To analyze quinolone resistance mechanisms in the set of isolates, DNA sequencing of the genes corresponding to the quinolone resistance-determining regions within the GyrA and ParC proteins was performed. We also assayed the intracellular sparfloxacin accumulation level in these gonococcal cells. Moreover, we performed pulsed-field gel electrophoresis analysis to determine whether the pretreatment and posttreatment isolates were isogenic. RESULTS: The minimum inhibitory concentration of sparfloxacin for the posttreatment isolate (4 micrograms/ml) was 16 times higher than that for the pretreatment isolate (0.25 microgram/ml). The pretreatment isolate contained three mutations, including a Ser-91 to Phe mutation and an Asp-95 to Asn mutation in GyrA and a Ser-88 to Pro mutation in ParC. The posttreatment isolate had four mutations, including the same three mutations and an additional Glu-91 to Gly mutation in ParC. The sparfloxacin accumulation level within 30 minutes in the posttreatment isolate was four times less than that in the pretreatment isolate. There were no differences in the pulsed-field gel electrophoresis patterns between the pretreatment and posttreatment isolates from the patient. CONCLUSIONS: The emergence of a fluoroquinolone-resistant N. gonorrhoeae isolate with multiple mutations involving GyrA and ParC reduced the response to sparfloxacin treatment. Multiple dosing and long-term treatment with sparfloxacin seems to induce a mutation in ParC and an alteration leading to reduced drug accumulation that contribute to increasing the fluoroquinolone resistance level.


Subject(s)
Anti-Infective Agents/pharmacology , Fluoroquinolones , Gonorrhea/drug therapy , Neisseria gonorrhoeae/drug effects , Quinolones/pharmacology , Adult , Drug Resistance, Microbial , Electrophoresis, Gel, Pulsed-Field , Humans , Male , Microbial Sensitivity Tests , Mutation , Neisseria gonorrhoeae/genetics , Neisseria gonorrhoeae/isolation & purification , Polymerase Chain Reaction , Treatment Failure
3.
Int J Urol ; 5(5): 471-5, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9781437

ABSTRACT

BACKGROUND: Until recently, epidemiologic studies of sexually transmitted diseases (STDs), including human immunodeficiency virus type-1 (HIV-1) infection, among Japanese female commercial sex workers and their patterns of condom use have been rare. We investigated trends in STDs among female commercial sex workers and their condom use patterns in Fukuoka, Japan, from 1990 through 1995. METHODS: The study group consisted of 1218 female commercial sex workers who attended an STD clinic to undergo screening for major STDs including chlamydial infection, gonorrhea and HIV-1 infection from 1990 through 1995. Endocervical smear specimens were taken from the women to detect Chlamydia trachomatis and Neisseria gonorrhoeae, and blood samples were obtained for the serologic diagnosis of HIV-1. Also, the commercial sex workers were interviewed concerning their condom use patterns. RESULTS: The annual infection and detection rates of C. trachomatis declined significantly from 58.1% in 1990 to 46.2% in 1995 and from 16.3% in 1990 to 10.0% in 1995, respectively, while the annual infection and detection rates of N. gonorrhoeae also declined significantly from 13.2% in 1990 to 3.5% in 1995 and from 1.5% in 1990 to 0.4% in 1995, respectively. None were found to be seropositive for HIV-1 during the 6-year period. The proportion of commercial sex workers using condoms significantly increased during 1992-1993 and 1994-1995 periods, as compared with the 1990-1991 period. CONCLUSION: Reductions in the prevalence of major STDs among female commercial sex workers may be related to an increase in the frequency of condom use.


Subject(s)
Chlamydia Infections/epidemiology , Gonorrhea/epidemiology , Sex Work , Adolescent , Adult , Chlamydia Infections/diagnosis , Chlamydia Infections/prevention & control , Chlamydia trachomatis/isolation & purification , Condoms/trends , Female , Gonorrhea/diagnosis , Gonorrhea/prevention & control , HIV Antibodies/analysis , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Infections/prevention & control , HIV-1/immunology , Humans , Incidence , Japan/epidemiology , Middle Aged , Neisseria gonorrhoeae/isolation & purification , Retrospective Studies , Urban Population
4.
Nihon Yakurigaku Zasshi ; 111(1): 45-53, 1998 Jan.
Article in Japanese | MEDLINE | ID: mdl-9551472

ABSTRACT

We have already reported that the concentration of nitric oxide (NO) increases during and after cerebral ischemia and a selective inhibitor of neuronal NO synthase (nNOS) suppresses this increase and subsequently mitigates brain damage in rats. Although the selective inhibition of nNOS is a promising pharmacological strategy for the treatment of stroke, the role of inducible NOS (iNOS) remains to be clarified. Toward this end, we investigated temporal alterations in iNOS mRNA by the RT-PCR method in a rat model of middle cerebral artery (MCA) occlusion. We found that iNOS mRNA in the ischemic hemisphere began to increase at 3 hr and reached the maximum level at 24 hr of reperfusion following 3 hr of MCA occlusion. However, quantitative analysis revealed that no significant difference existed between 6 hr or 24 hr reperfusion group and their respective time-matched sham operation group. In addition, neither Western blotting nor immunocytochemical study disclosed an apparent induction of iNOS at any time points examined. Similar results were obtained at 24 hr of permanent MCA occlusion. Taken together, these data indicate that iNOS induction during and after MCA occlusion may be not a critical event for the development of infarction caused by ischemia itself.


Subject(s)
Cerebral Infarction/enzymology , Nitric Oxide Synthase/biosynthesis , Animals , Arterial Occlusive Diseases/enzymology , Brain/metabolism , Cerebral Arterial Diseases/enzymology , Disease Models, Animal , Enzyme Induction , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II , Rats , Reperfusion Injury/enzymology
5.
Sex Transm Infect ; 74(6): 435-8, 1998 Dec.
Article in English | MEDLINE | ID: mdl-10195054

ABSTRACT

OBJECTIVE: To evaluate the performance of a new improved enzyme immunoassay (EIA) kit for the detection of Chlamydia trachomatis in vaginal swab and endocervical swab specimens from female commercial sex workers, in comparison with a conventional EIA test and a polymerase chain reaction (PCR) assay. METHODS: A high risk group of 163 female commercial sex workers who visited a sexually transmitted disease (STD) clinic in order to undergo screening for major STDs, including chlamydial infection, were enrolled. A total of four swab specimens, including two vaginal and two endocervical specimens, were collected from each woman by a clinician. To identify C trachomatis, a new improved EIA kit (IDEIA PCE), a conventional EIA kit (IDEIA), and PCR assay (Amplicor) were used. Discrepancies in the results were resolved using supplementary PCR assay. A female patient was considered to be infected with C trachomatis if the IDEIA PCE test and PCR test for both sample sites (endocervical and vaginal) gave positive results. Following resolution of these discrepancies, relative sensitivity and specificity, confidence intervals, and predictive values for each type of specimen by each assay were calculated. RESULTS: Of the 163 women tested, 35 (21.5%) were shown to be infected with C trachomatis. The relative sensitivities in vaginal swab specimens were 88.8%, 68.6%, and 91.4% using IDEIA PCE, IDEIA, and PCR, respectively. The relative specificities in vaginal swab specimens were 99.2%, 99.2%, and 100%, respectively. The relative sensitivities in endocervical swab specimens were 85.7%, 77.1%, and 91.4% with IDEIA PCE, IDEIA, and PCR, respectively. The relative specificities in endocervical swab specimens were all 100%. CONCLUSIONS: The results obtained in this study suggest that the sensitivity and specificity of IDEIA PCE test on vaginal swab and endocervical swab specimens were similar to those of PCR assay on the two types of specimen. It is concluded that IDEIA PCE test on vaginal swab specimens is an acceptable, sensitive, and less invasive approach for the detection of C trachomatis in commercial sex workers with a high prevalence of C trachomatis infection.


Subject(s)
Chlamydia Infections/diagnosis , Immunoenzyme Techniques/methods , Sex Work , Adult , Chlamydia Infections/microbiology , Chlamydia trachomatis/isolation & purification , Female , Humans , Polymerase Chain Reaction/methods , Risk Factors , Uterine Cervical Diseases/diagnosis , Uterine Cervical Diseases/microbiology , Vaginal Diseases/diagnosis , Vaginal Diseases/microbiology
6.
Neurol Res ; 19(2): 192-203, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9175150

ABSTRACT

The present study aimed to examine the effects of N omega-nitro-L-arginine (LNA) on the early ischemic neuronal damage (EIND). All the experiments were carried out under general anesthesia, maintaining the blood gases and the body temperature within the physiological ranges. The local CBF, the topographically corresponding cortical specific gravity, and the volume of EIND were determined in each rat, which was subjected to prolonged or temporary occlusion of middle cerebral artery (MCA) using our original miniclip. Significant cortical edema developed only in the brain area where the local CBF value was below 200 ml 100 g-1 min-1. The prolonged MCA occlusion for 1, 2, and 4 h induced a time-dependent increase in the severity of cortical edema and the volume of EIND. Removal of the clip invariably induced recirculation. Compared to that induced by 4 h prolonged ischemia, the brain damage was improved by 1 h MCA occlusion followed by 3 h recirculation, whereas it was significantly worsened by 2 h ischemia followed by 2 h recirculation. While LNA [1 mg, i.p., given two times during the experiment] only partially inhibited the activity of brain nitric oxide synthase, it remarkably ameliorated EIND of both prolonged ischemia and recirculation in this model. The above findings indicate the pathogenic role of nitric oxide in prolonged ischemia as well as recirculation.


Subject(s)
Brain Ischemia/pathology , Enzyme Inhibitors/pharmacology , Neurons/pathology , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine/pharmacology , Reperfusion Injury/pathology , Animals , Blood Pressure/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , Chronic Disease , Rats , Specific Gravity/drug effects , Time Factors
7.
Chemotherapy ; 42(4): 280-5, 1996.
Article in English | MEDLINE | ID: mdl-8804796

ABSTRACT

New quinolone (NQ) antimicrobials may influence the functions of polymorphonuclear leukocyes (PMNs). Fleroxacin (FLRX), one of the newer NQs which has a long half-life in blood and a strong bactericidal effect, was examined for its influence on superoxide production by PMNs. Augmentation of superoxide production by PMNs when stimulated with phorbol myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine (fMLP) was observed following the addition of 25, 50, 100 and 200 micrograms/ml of FLRX. In addition, the effects of staurosporine and H-7, inhibitors of protein kinase C (PKC), and of genistein, a tyrosine kinase (TK) inhibitor, on FLRX-enhanced superoxide production were examined. Superoxide production augmented by FLRX was diminished by the addition of staurosporine and H-7, when PMNs were stimulated with PMA, and by the addition of genistein, when PMNs were stimulated with fMLP. These results suggest that FLRX augments superoxide production by PMNs through enhancing the activities of phosphorylation by PKC or TK within the signal transduction pathway in PMNs.


Subject(s)
Anti-Infective Agents/pharmacology , Fleroxacin/pharmacology , Neutrophils/metabolism , Protein Kinases/physiology , Superoxides/blood , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Carcinogens/pharmacology , Enzyme Inhibitors/pharmacology , Genistein , Humans , In Vitro Techniques , Isoflavones/pharmacology , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Neutrophils/drug effects , Neutrophils/enzymology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/blood , Protein Kinase C/physiology , Protein Kinases/blood , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/blood , Protein-Tyrosine Kinases/physiology , Signal Transduction/drug effects , Staurosporine/pharmacology , Tetradecanoylphorbol Acetate/pharmacology
8.
Int J Antimicrob Agents ; 6(2): 85-9, 1995 Dec.
Article in English | MEDLINE | ID: mdl-18611690

ABSTRACT

Many antimicrobial agents including new quinolones (NQs) influence the cellular defense mechanisms such as polymorphonuclear leukocytes (PMNs), macrophages and lymphocytes. We examined the effects of NQs on superoxide (SO) production of PMNs following stimulation of phorbol myristate acetate (PMA). Ofloxacin (OFLX) and fleroxacin (FLRX) significantly augmented SO production of PMNs compared to lomefloxacin, sparfloxacin. Staurosporin and H-7, specific inhibitors of protein kinase C of SO production pathway in PMNs, inhibited augmented SO production by OFLX and FLRX in the concentration-dependent manner. NADPH oxidase activity was not influenced by OFLX in cell lysate assay system. These results suggest that OFLX and FLRX augmented PMN function through enhancing protein kinase activity, but not through direct enhancement of NADPH oxidase.

9.
Mol Chem Neuropathol ; 26(2): 107-57, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8573240

ABSTRACT

The results of our continuing studies on the role of nitric oxide (NO) in cellular mechanisms of ischemic brain damage as well as related reports from other laboratories are summarized in this paper. Repetitive ip administration of NG-nitro-L-arginine (L-NNA), a NO synthase (NOS) inhibitor, protected against neuronal necrosis in the gerbil hippocampal CA1 field after transient forebrain ischemia with a bell-shaped response curve, the optimal dose being 3 mg/kg. Repeated ip administration of L-NNA also mitigated rat brain edema or infarction following permanent and transient middle cerebral artery (MCA) occlusion with a U-shaped response. The significantly ameliorative dose-range and optimal dose were 0.01-1 mg/kg and 0.03 mg/kg, respectively. Studies using a NO-sensitive microelectrode revealed that NO concentration in the affected hemisphere was remarkably increased by 15-45 min and subsequently by 1.5-4 h after MCA occlusion. Restoration of blood flow after 2 h-MCA occlusion resulted in enhanced NO production by 1-2 h after reperfusion. Administration of L-NNA (1 mg/kg, ip) diminished the increments in NO production during ischemia and reperfusion, leading to a remarkable reduction in infarct volume. In brain microvessels obtained from the affected hemisphere, Ca(2+)-dependent constitutive NOS (cNOS) was activated significantly at 15 min, and Ca(2+)-independent inducible NOS (iNOS) was activated invariably at 4 h and 24 h after MCA occlusion. Two hour reperfusion following 2 h-MCA occlusion caused more than fivefold increases in cNOS activity with no apparent alterations in iNOS activity. Thus, we report here based on available evidence that there is good reason to think that NOS activation in brain microvessels may play a role in the cellular mechanisms underlying ischemic brain injury.


Subject(s)
Brain/drug effects , Ischemic Attack, Transient/enzymology , Nitric Oxide Synthase/drug effects , Nitric Oxide/physiology , Animals , Brain/blood supply , Brain/enzymology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Ischemic Attack, Transient/pathology , Ischemic Attack, Transient/physiopathology , Microcirculation/drug effects , Nitric Oxide/biosynthesis , Prosencephalon/drug effects , Rats
10.
Neuroreport ; 6(11): 1541-5, 1995 Jul 31.
Article in English | MEDLINE | ID: mdl-7579144

ABSTRACT

Our newly synthesized delta-(S-methylisothioureido)-L-norvaline (L-MIN) was shown to have potent inhibitory effects on Ca(2+)-dependent and constitutively expressed neuronal nitric oxide synthase (type I NOS) when compared to other commonly recognized NOS inhibitors and produced an IC50 value of 5.7 nM. By contrast, this compound exhibited more than 40-fold weaker inhibitory effects on the other NOS isoforms. Administration of L-MIN (0.1, 0.3 and 1 mg kg-1, i.p.) to rats immediately after 2 h middle cerebral artery occlusion and 2 h reperfusion reduced infarct size in a dose-dependent manner. These results suggest that type I NOS activation has a crucial role in the pathogenic cellular mechanisms underlying cerebral ischaemia.


Subject(s)
Citrulline/analogs & derivatives , Enzyme Inhibitors/pharmacology , Ischemic Attack, Transient/drug therapy , Neuroprotective Agents/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Thiourea/analogs & derivatives , Analysis of Variance , Animals , Arterial Occlusive Diseases/complications , Cerebral Arteries , Citrulline/pharmacology , Disease Models, Animal , Evaluation Studies as Topic , Ischemic Attack, Transient/etiology , Isoenzymes/antagonists & inhibitors , Male , Rats , Rats, Sprague-Dawley , Thiourea/pharmacology
11.
Chemotherapy ; 41(3): 208-13, 1995.
Article in English | MEDLINE | ID: mdl-7656668

ABSTRACT

Renal scarring, which occurs following refluxing pyelonephritis, is considered to be involved in the development of reflux nephropathy. Prevention of renal scar formation requires immediate initiation of antimicrobial treatment; treatment delay results in renal scarring. We demonstrate that Ebselen, an antioxidant agent, given at a dose of 15 mg/kg twice a day prevents renal scarring in rats following direct renal parenchymal bacterial inoculation. In addition, using an ascending pyelonephritis model, which clinically resembles refluxing pyelonephritis in humans, we show that when initiation of antimicrobial treatment was delayed, coadministration of Ebselen prevents renal scar formation. These results show that Ebselen is effective in preventing renal scarring and suggest that the clinical use of this drug may prevent renal scar formation following pyelonephritis and progression to reflux nephropathy.


Subject(s)
Azoles/therapeutic use , Ciprofloxacin/therapeutic use , Organoselenium Compounds/therapeutic use , Pyelonephritis/prevention & control , Animals , Bacteria/growth & development , Cicatrix/prevention & control , Colony Count, Microbial , Female , Isoindoles , Pyelonephritis/microbiology , Rats , Rats, Sprague-Dawley , Time Factors
13.
Acta Neurochir (Wien) ; 126(2-4): 165-9, 1994.
Article in English | MEDLINE | ID: mdl-8042550

ABSTRACT

The present study is aimed at examining the therapeutic effect of Nicorandil on chronic vasospasm using beagle dogs subjected to a "two-haemorrhage" insult, as well as its dilatory effect on the PDA [phorbol-12,13 diacetate]-induced contraction of the canine basilar artery. 1. A total of 12 animals of either sex, weighing 7 to 12 kg, were assigned into saline control and Nicorandil-treated groups. Immediately after the second induction of subarachnoid haemorrhage (SAH), animals started to receive the agent via the venous route at the constant rate of 10 micrograms/kg/minute for six hours (day 3). On days 4, 5, and 6, the drug was given twice at the same rate for three hours. After the final angiograms, animals were sacrificed by exsanguination. 2. Using ring specimen of the canine basilar artery at a resting tension of 3 g, isometric tension was monitored to examine the effect of Nicorandil on PDA induced contraction. Nicorandil significantly ameliorated chronic vasospasm and inhibited PDA-induced contraction in a dose-dependent fashion. The present data indicate that Nicorandil provides a useful way of treating chronic vasospasm after SAH.


Subject(s)
Ischemic Attack, Transient/physiopathology , Niacinamide/analogs & derivatives , Vascular Resistance/drug effects , Vasodilator Agents/pharmacology , Animals , Basilar Artery/drug effects , Basilar Artery/physiopathology , Chronic Disease , Dogs , Female , Male , Niacinamide/pharmacology , Nicorandil , Protein Kinase C/physiology , Subarachnoid Hemorrhage/physiopathology , Vascular Resistance/physiology
14.
Article in English | MEDLINE | ID: mdl-7526623

ABSTRACT

The present study was aimed at determining chronological alterations of Ca2+/calmodulin (CaM)-dependent and -independent nitric oxide synthase (NOS) activities in brain microvessels (MV) isolated from the affected hemisphere following an occlusion of the middle cerebral artery (MCAo) in rats. It was shown that significant enhancements of Ca2+/CaM-independent NOS activity to 922% and 920% of control level were manifested at 4 h and 24 h, respectively, which returned to the control level at 48 h after MCAo. Regarding Ca2+/CaM-dependent NOS, on the other hand, it was shown that the activity was invariably increased to 374% and 743% of control level at 48 h and 1 week following MCAo, respectively. Thus, the present study provided the first evidence that two distinct types of NOS activities were increased with different temporal patterns after MCAo. These heterogeneous alterations of NOS activities may be of critical importance for the induction of brain damage following cerebral ischemia.


Subject(s)
Amino Acid Oxidoreductases/physiology , Brain Damage, Chronic/physiopathology , Brain Edema/physiopathology , Brain Ischemia/physiopathology , Brain/blood supply , Calcium/physiology , Calmodulin/physiology , Amino Acid Oxidoreductases/classification , Animals , Male , Microcirculation/physiopathology , Nitric Oxide Synthase , Rats , Rats, Sprague-Dawley
15.
Eur J Pharmacol ; 248(4): 325-8, 1993 Dec 01.
Article in English | MEDLINE | ID: mdl-7514138

ABSTRACT

N omega-nitro-L-arginine (0.3-10 mg/kg), a nitric oxide (NO) synthase inhibitor, was administered i.p. to gerbils subjected to 10 min of carotid artery occlusion seven times at 5 min, 3, 6, 24, 48, 72 and 96 h after recirculation. Histopathological examination of the brains obtained 6 days after reflow disclosed that N omega-nitro-L-arginine possesses an ability to mitigate neuronal necrosis in the CA1 subfield of the hippocampus with an optimal dosage of 3 mg/kg. These results strongly suggest that NO synthase activation is at least partly involved in the pathogenetic cellular mechanisms underlying selective neuronal necrosis following cerebral ischemia.


Subject(s)
Amino Acid Oxidoreductases/antagonists & inhibitors , Arginine/analogs & derivatives , Ischemic Attack, Transient/drug therapy , Animals , Arginine/therapeutic use , Dose-Response Relationship, Drug , Gerbillinae , Hippocampus/pathology , Image Processing, Computer-Assisted , Injections, Intraperitoneal , Male , Necrosis , Neurons/pathology , Nitric Oxide Synthase , Nitroarginine
16.
J Cereb Blood Flow Metab ; 13(3): 409-15, 1993 May.
Article in English | MEDLINE | ID: mdl-8478399

ABSTRACT

Changes in protein kinase C (PKC) activity, membrane lipid metabolism, and the extent of 20-kDa myosin light chain (MLC) phosphorylation in spastic cerebral basilar arteries were examined by using the beagle "two-hemorrhage" model of subarachnoid hemorrhage. In spastic arteries at days 4 and 7, cytosolic PKC activity showed a decrease of 40-45% with no significant changes in membrane PKC activity as compared with nonspastic control arteries. Cytosolic PKC activity of the day 14 arteries returned toward the normal control level with the remission of vasospasm. Western blot analysis of the PKC isoforms revealed that the amounts of PKC alpha and PKC epsilon but not PKC zeta were decreased in spastic arteries. As compared with nonspastic arteries, spastic arteries showed higher rates of incorporation of [3H]choline into phosphatidylcholine (PC) and [14C]ethanolamine into phosphatidylethanolamine (PE), but not of [3H]myoinositol into phosphoinositides, suggesting the stimulated turn-over of PC and PE. The extent of 20-kDa MLC phosphorylation was not increased in the spastic arteries at days 4 or 7 as compared with that in the nonspastic control arteries. These results demonstrate that PKC activity and related membrane lipid metabolism are altered in spastic basilar arteries after subarachnoid hemorrhage.


Subject(s)
Ischemic Attack, Transient/metabolism , Membrane Lipids/metabolism , Protein Kinase C/metabolism , Subarachnoid Hemorrhage/complications , Animals , Basilar Artery/metabolism , Blotting, Western , Diglycerides/biosynthesis , Dogs , Ischemic Attack, Transient/etiology , Isoenzymes/metabolism , Male , Myosins/chemistry , Myosins/metabolism , Phospholipids/metabolism , Phosphorylation , Subcellular Fractions/metabolism
17.
Chemotherapy ; 39(1): 70-6, 1993.
Article in English | MEDLINE | ID: mdl-8383032

ABSTRACT

Polymorphonuclear neutrophils (PMN) represent an important defense mechanism against bacterial infection. Superoxide is one of the most important factors released by PMN following various stimulations including bacteria. Augmentation of chemiluminescence response of PMN stimulated by phorbol myristate acetate was observed following the addition of 25-200 micrograms/ml of ofloxacin, a new quinolone antimicrobial agent. In addition, the effects of two inhibitors of protein kinase C, staurosporine and H-7, were examined. The augmented superoxide production was inhibited by 1 or 2 microM of staurosporine or 50 or 100 microM of H-7. These results suggest that ofloxacin augments superoxide production of PMN and that this augmentation is probably due to the enhancement of leukocyte protein kinase C.


Subject(s)
Neutrophils/metabolism , Ofloxacin/pharmacology , Protein Kinase C/antagonists & inhibitors , Superoxides/metabolism , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine , Alkaloids/pharmacology , Isoquinolines/pharmacology , Luminescent Measurements , Neutrophils/drug effects , Piperazines/pharmacology , Protein Kinase Inhibitors , Protein Kinases/pharmacology , Staurosporine
18.
Neurosci Lett ; 147(2): 159-62, 1992 Dec 07.
Article in English | MEDLINE | ID: mdl-1491800

ABSTRACT

In order to investigate whether or not nitric oxide (NO) formation underlies the cellular mechanisms of ischemic brain damage, we examined the effects of N omega-nitro-L-arginine (L-NNA), a NO synthase inhibitor, on ischemic brain edema and subsequent infarction in rats with middle cerebral artery occlusion (MCAo). For this purpose, administrations of L-NNA (1 mg/kg, i.p.) to each animal were done at the time of 5 min, 3, 6 and 24 h after MCAo, respectively. It was shown from this study that L-NNA significantly mitigated ischemic cerebral edema, and histological examinations revealed that this compound markedly reduced infarction size that occurred following MCAo. These results strongly suggest that NO formation is at least partly involved in the pathogenetic mechanisms of ischemic brain edema and subsequent cerebral infarction.


Subject(s)
Arginine/analogs & derivatives , Brain Chemistry/drug effects , Brain Edema/drug therapy , Brain Ischemia/drug therapy , Cerebral Infarction/drug therapy , Nitric Oxide/metabolism , Animals , Arginine/therapeutic use , Cerebral Arteries/physiology , Male , Nitroarginine , Potassium/metabolism , Rats , Rats, Sprague-Dawley , Sodium/metabolism
19.
Brain Res ; 571(2): 265-71, 1992 Feb 07.
Article in English | MEDLINE | ID: mdl-1535268

ABSTRACT

In order to investigate the role of Na+,K(+)-ATPase in the development of neuronal necrosis following cerebral ischemia, ischemia was induced in gerbils by occluding the common carotid artery unilaterally for 10 min. A time-course analysis revealed that significant reductions of the Na+,K(+)-ATPase activity in the cerebral cortex and hippocampus were manifested at 15 min, 30 min, and 1 h, and returned to the control level one day following recirculation. No apparent alterations of the Mg(2+)-ATPase activity, on the other hand, were obtained throughout the experimental period. Furthermore, Scatchard analyses of [3H]ouabain binding to the cerebral cortex membranes disclosed that the Bmax values invariably decreased without any change of Kd values following ischemia. It has also been shown that treatment of the animals with an agent known to mitigate ischemic neuronal necrosis, i.e. BY-1949, significantly reversed such derangements. These results suggest that the recovery of decreased Na+,K(+)-ATPase activity shortly after ischemia exerts a protective effect against ischemic brain damage.


Subject(s)
Cerebral Cortex/enzymology , Dibenzoxazepines/pharmacology , Hippocampus/enzymology , Ischemic Attack, Transient/enzymology , Neurons/enzymology , Vasodilator Agents/pharmacology , Vinca Alkaloids/pharmacology , Animals , Ca(2+) Mg(2+)-ATPase/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , Gerbillinae , Hippocampus/drug effects , Hippocampus/pathology , Ischemic Attack, Transient/pathology , Kinetics , Male , Necrosis , Neurons/pathology , Ouabain/metabolism , Reference Values , Time Factors
20.
J Neurochem ; 58(1): 362-8, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1345768

ABSTRACT

In search of factors mitigating the final outcome of ischemic and epileptic brain damage, we tested a novel dibenzoxazepine derivative (BY-1949), as the compound has been shown to be effective under these two conditions. First, using rat brain, we assessed whether or not BY-1949 affects the Na+,K(+)-ATPase activity. Although in vitro applications of either BY-1949 or its three major metabolites did not cause any apparent effects, both acute and chronic oral administrations of the compound (10 mg/kg) invariably increased the Na+,K(+)-ATPase activity in the synaptosomal plasma membranes by increasing Vmax values. Second, it was shown by this study that the drug treatment caused marked increases in the uptake of both glutamic acid and gamma-aminobutyric acid into the synaptosomes. These results suggest that the activity against ischemic/epileptic brain damage by BY-1949 is explicable, at least partly, in terms of improvement of ionic derangements across the neural membranes via Na+,K(+)-ATPase activation.


Subject(s)
Brain/enzymology , Dibenzoxazepines/pharmacology , Neurotransmitter Agents/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Synaptosomes/enzymology , Animals , Brain/metabolism , Cell Membrane/metabolism , Enzyme Activation , Glutamates/pharmacokinetics , Glutamic Acid , Kinetics , Male , Rats , Rats, Inbred F344 , Synaptosomes/metabolism , gamma-Aminobutyric Acid/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...